Document is current
Any future updates will be listed below
-
Authors
Watt, April C. https://orcid.org/0000-0002-5145-5334
Ahn, Antonio
Blyth, Catherine https://orcid.org/0000-0002-6653-1723
Dixon-Douglas, Julia R.
Ambani, Krutika
Coulson, Rhiannon
Taylor, Michael https://orcid.org/0000-0003-1115-5449
Chan, Keefe T. https://orcid.org/0000-0001-6114-3724
Dietrich, Catherine
Russ, Brendan E. https://orcid.org/0000-0001-6862-5283
Ramm, Susanne
Mahendra, Christabella A.
Lu, Kun-Hui
Pires, Nichelle https://orcid.org/0000-0002-0485-2927
Garcia-Sannicolas, Jesus https://orcid.org/0009-0007-2344-1246
Voulgaris, Olivia https://orcid.org/0009-0008-1168-8521
Nunag, Sheena
Ang, Ching-Seng
Dawson, Mark A. https://orcid.org/0000-0002-5464-5029
Lim, Elgene https://orcid.org/0000-0001-8065-8838
Arnedos, Monica
Chandarlapaty, Sarat https://orcid.org/0000-0003-4532-8053
André, Fabrice https://orcid.org/0000-0001-5795-8357
Goel, Shom https://orcid.org/0000-0001-8329-9084
- License Information
-
More Information
Article History
Received: 26 August 2025
Accepted: 6 July 2026
First Online: 12 August 2026
Ethics
Competing interests: S.G. has received research funding from Eli Lilly, G1 Therapeutic and Incyclix Bio; and served as a paid advisor for Eli Lilly, Pfizer, Novartis, BeiGene, Belharra Therapeutics and Halda Therapeutics. J.R.D.-D. has received support of travel and accommodation expenses from Pierre Fabre, MSD and Novartis; and received personal honoraria from Gilead Life Sciences. M.A. has received research funding from AstraZeneca and Roche-Genentech; served as a paid advisor for Eli Lilly, Novartis, AstraZeneca, Gilead, Daiichi-Sankyo, Menarini and Pfizer; and received travel grants from Novartis, AstraZeneca, Eli-Lilly and Daiichi-Sankyo. S.C. has received institutional grant funding from Daiichi-Sankyo and AstraZeneca; holds share options in Totus Medicines; and received honoraria as a consultant to Daiichi-Sankyo, AstraZeneca, Lilly, Casdin Capital, Merck, Nuvalent and Pathos AI. F.A. has received research grants or advisory board funds (paid to institutions) from AstraZeneca, Daiichi-Sankyo, Lilly, Novartis, BMS, Pfizer, Relay Therapeutics and Roche; and received honoraria from Relay Therapeutics, Lilly and AstraZeneca.
